Neurosoft Bioelectronics

About
What does Neurosoft Bioelectronics do?
Neurosoft Bioelectronics is a startup focused on creating advanced brain-computer interface (BCI) technology. Their core innovation lies in developing soft and stretchable BCI platforms designed for seamless integration with the brain. The company recently secured a $7.5 million oversubscribed seed funding round to accelerate the scaling of its technology.
What is Neurosoft Bioelectronics's revenue?
StartupHub estimates Neurosoft Bioelectronics's annual revenue at $2.2M (range $1.2M to $6.9M, 68% confidence), based on comparable companies in the sector.
What is Neurosoft Bioelectronics's valuation?
StartupHub estimates Neurosoft Bioelectronics's effective valuation at $28.7M (range $18.8M to $45.0M, 10% confidence), based on comparable companies in the sector.
How much funding has Neurosoft Bioelectronics raised?
Neurosoft Bioelectronics has raised a total of $8M in funding. The most recent round on record is Seed.
Where is Neurosoft Bioelectronics headquartered?
Neurosoft Bioelectronics is headquartered in Geneva, Switzerland.
When was Neurosoft Bioelectronics founded?
Neurosoft Bioelectronics was founded in 2021.
What industry does Neurosoft Bioelectronics operate in?
Neurosoft Bioelectronics operates in Biotechnology, Medical Devices, Neurotechnology, Artificial Intelligence, Neurotech & HCI, Brain-Computer Interface.
How many employees does Neurosoft Bioelectronics have?
Neurosoft Bioelectronics has approximately 18 people on record.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.